This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-102920-z5q3wo7v | Insight from ACE2-S- Protein Interactions Middle East respiratory syndrome coronavirus( MERS- CoV): animal to human interaction MERS- CoV: the intermediate host identified? |
| cord-253438-k8iqv1jb | A novel coronavirus from patients with pneumonia in China Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Are pangolins the intermediate host of the 2019 novel coronavirus( SARS- CoV-2)? |
| cord-183197-dxmto1tu | In Healthcare Workers with Ongoing High Risk Exposure to COVID-19 Prophylaxis with tetracyclines in ards: Potential therapy for covid-19-induced ards? |
| cord-276493-hoaxv5e0 | a casepopulation study Anti- HCV, nucleotide inhibitors, repurposing against COVID-19 Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-252919-647zcjgu | NL63: a clinically important virus? |
| cord-281005-6gi18vka | Why are RNA virus mutation rates so damn high? |
| cord-296657-mymndjvd | Why are RNA virus mutation rates so damn high? |
| cord-256156-mywhe6w9 | How good is automated protein docking? |
| cord-256156-mywhe6w9 | True Receptors or Adaptation Bias? |
| cord-262043-66qle52a | bioRxiv Is it reliable to use common molecular docking methods for comparing the binding affinities of enantiomer pairs for their protein target? |
| cord-262043-66qle52a | protein Are scoring functions in protein Àprotein docking ready to predict interactomes? |
| cord-275185-9br8lwma | The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta- analysis Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A( H1N1) 2009 virus infection Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience Clinical characteristics of 26 human cases of highly pathogenic avian influenza A( H5N1) virus infection in China Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea Treatment of 5 critically Ill patients With COVID-19 with convalescent plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Treatment with convalescent plasma for critically Ill patients with SARS- CoV-2 infection Treatment with convalescent plasma for COVID-19 patients in Wuhan Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea clinicalmanagement- of- severe- acute- respiratory- infection- when- novel- coronavirus-(ncov)-infection- is- suspected Guideline for diagnosis and treatment for novel coronavirus pneumonia Establishment and validation of a pseudovirus neutralization assay for SARS- CoV-2 Meta- analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? |
| cord-275185-9br8lwma | why and how? |
| cord-263167-es806qhz | What do our results suggest for SARS- CoV-2 vaccine design? |
| cord-319590-f9qcabcx | : What Are the Next Steps? |
| cord-309411-2dfiwo65 | What are the implications of this transition state found in CoV1 but not in CoV2 at neutral pH? |
| cord-263090-29n9tsk9 | Identifying SARS- CoV-2 related coronaviruses in Malayan pangolins Structure, Function, and Evolution of Coronavirus Spike Proteins Cryo- EM structure of the 2019-nCoV spike in the prefusion conformation Structure, Function, and Antigenicity of the SARS- CoV-2 Spike Glycoprotein Structural basis for the recognition of SARS- CoV-2 by full- length human ACE2 Cryo- electron microscopy structures of the SARS- CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding The 3.1-Angstrom Cryo- electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation Cryo- EM structures of MERS- CoV and SARS- CoV spike glycoproteins reveal the dynamic receptor binding domains SARS- CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor A highly conserved cryptic epitope in the receptor- binding domains of SARS- CoV-2 and SARS- CoV Topological and energetic factors: what determines the structural details of the transition state ensemble and"en- route"intermediates for protein folding? |
| cord-263090-29n9tsk9 | Identifying SARS- CoV-2 related coronaviruses in Malayan pangolins Structure, Function, and Evolution of Coronavirus Spike Proteins Cryo- EM structure of the 2019-nCoV spike in the prefusion conformation Structure, Function, and Antigenicity of the SARS- CoV-2 Spike Glycoprotein Structural basis for the recognition of SARS- CoV-2 by full- length human ACE2 Cryo- electron microscopy structures of the SARS- CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding The 3.1-Angstrom Cryo- electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation Cryo- EM structures of MERS- CoV and SARS- CoV spike glycoproteins reveal the dynamic receptor binding domains SARS- CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor A highly conserved cryptic epitope in the receptor- binding domains of SARS- CoV-2 and SARS- CoV Topological and energetic factors: what determines the structural details of the transition state ensemble and"en- route"intermediates for protein folding? |
| cord-280941-ds6x0yym | How will HPV vaccines affect cervical cancer? |
| cord-280941-ds6x0yym | The composition and the structure of bacterioferritin of Escherichia coli Self- assembly in the ferritin nano- cage protein superfamily Presenting native- like trimeric HIV-1 antigens with self- assembling nanoparticles Hemagglutinin- stem nanoparticles generate heterosubtypic influenza protection Ferritin nanocages: great potential as clinically translatable drug delivery vehicles? |
| cord-305742-wf6qxplf | What is Life? |
| cord-291420-40xsypzt | Can we gain valuable insights regarding RBD- ACE2 interface formation by analyzing these mutations? |
| cord-291420-40xsypzt | What are the mutations acquired on RBD during COVID-19 and what are the interfacial molecular rearrangements induced by these mutations? |
| cord-310230-9wfb43gt | Enhanced Receptor Binding of SARS- CoV-2 through Networks of Hydrogen- Bonding and Hydrophobic Interactions Is the Rigidity of SARS- CoV-2 Spike Receptor- Binding Motif the Hallmark for Its Enhanced Infectivity? |
| cord-310230-9wfb43gt | Insights from All- Atom Simulations Characterization of the Receptor- Binding Domain( RBD) of 2019 Novel Coronavirus: Implication for Development of RBD Protein as a Viral Attachment Inhibitor and Vaccine Structural and Functional Basis of SARS- CoV-2 Entry by Using Human ACE2 Phylogenetic Network Analysis of SARS- CoV-2 Genomes Is the Rigidity of SARS- CoV-2 Spike Receptor- Binding Motif the Hallmark for Its Enhanced Infectivity? |
| cord-290290-wyx9ib7s | gp120 Interactions with alpha4beta7 Structure, Function, and Antigenicity of the SARS- CoV-2 Spike Glycoprotein Testing for responses to the wrong SARS- CoV-2 antigen? |
| cord-287205-k64svq6n | Will COVID-19 538 become the next neglected tropical disease? |
| cord-285900-3rr0j5tk | How can we quantitatively evaluate the epitopes'neutralizing immunogenicity? |
| cord-329392-fufattj8 | medRxiv The role of antibody testing for SARS- CoV-2: is there one? |
| cord-281793-tj4m01s4 | Could such antibodies be cross- reactive with other SARS- related CoVs( SARSr- CoVs)? |
| cord-281793-tj4m01s4 | Could such cross- reactive antibodies have neutralizing activities for all SARSr- CoVs? |
| cord-281793-tj4m01s4 | What would be ideal targets or epitopes for cross- neutralizing antibodies? |
| cord-267001-csgmc155 | The adjuvant GLA- SE promotes human Tfh cell expansion and emergence of public TCRbeta clonotypes Can follicular helper T cells be targeted to improve vaccine efficacy? |
| cord-267001-csgmc155 | Where is the cut- off? |
| cord-296187-nnv2e7gr | A small molecule- kinase interaction map for clinical kinase inhibitors Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule- specific drugs? |
| cord-332134-88wfcc3y | How good are my data and what is the resolution? |
| cord-309898-sju15hev | Recent insights into emerging coronaviruses Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia MERS in South Korea and China: A potential outbreak threat? |
| cord-309898-sju15hev | SARS- CoV-2 Have Arisen via Serial Passage through an Animal Host or Cell Culture?: |
| cord-265697-bbvlowyo | animal to human interaction MERS- CoV: the intermediate host identified? |
| cord-332185-a96r1k7a | 437 pangolins Isolation of SARS- CoV-2-related coronavirus from Malayan 439 pangolins Are pangolins the intermediate host of the 2019 novel 441 coronavirus( SARS- CoV-2)? |
| cord-339093-mwxkvwaz | Engineered Autonomous Human Variable Domains Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents? |
| cord-291790-z5rwznmv | Which Genetic 594 Mutations Are Antigenically Important? |
| cord-291790-z5rwznmv | Why are RNA virus mutation rates so damn high? |
| cord-336150-l8w7xk0b | hospitalists'perspective Broad- spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Coronavirus: epidemiology, genome replication and the interactions with their hosts Characterization of the receptorbinding domain( RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine Differential stepwise evolution of SARS coronavirus functional proteins in different host species Dexamethasone for COVID-19? |
| cord-333089-ufyzqgqk | Circulating plasma concentrations of angiotensin- converting enzyme 2 in men and women with heart failure and effects of renin- angiotensin- aldosterone inhibitors Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta- analysis Impact of sex and gender on COVID-19 outcomes in Europe Are sex discordant outcomes in COVID-19 related to sex hormones? |
| cord-328189-jpkxjn6e | This comparison raises the following question: How does SARS-2002 RBD reach an ACE2 binding affinity that is comparable to that of COVID-19 but with fewer contact pairs and a smaller interface area? |
| cord-339724-roj8ksvc | the beginning of another SARS- like pandemic? |
| cord-319855-78xmxymu | Are sufficient details of methods and analysis provided to allow replication by others? |
| cord-319855-78xmxymu | Yes Are all the source data underlying the results available to ensure full reproducibility? |
| cord-353748-y1a52z8e | Bacteriocins-a viable alternative to antibiotics? |
| cord-332855-u0amf1oh | The rhesus rotavirus VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site Unique carbohydrate- carbohydrate interactions are required for high affinity binding between Fc ␥ RIII and antibodies lacking core fucose Model system for cell adhesion mediated by weak carbohydrate- carbohydrate interactions Carbohydrate- carbohydrate interaction as a major force initiating cell- cell recognition Tn and STn are members of a family of carbohydrate tumor antigens that possess carbohydrate- carbohydrate interactions Are Lewis b and H type 1 on Helicobacter pylori involved in binding of bacteria to MUC1 mucin? |
| cord-347587-auook38y | Molecular evolution of MERS coronavirus: dromedaries as a recent intermediate host or longtime animal reservoir? |
| cord-354868-pqn59ojj | The protein complex crystallography beamline( BL19U1) at the Shanghai 545 Synchrotron Radiation Facility How good are my data and what is the resolution? |
| cord-328003-yovp8squ | What Are the Most Powerful Immunogen Design Vaccine Strategies? |
| cord-328003-yovp8squ | What Are the Most Powerful Immunogen Design Vaccine Strategies? |
| cord-355807-q3bngari | : Where are we? |
| cord-295482-qffg6r91 | What can we predict about viral evolution and emergence? |
| cord-352527-eeyqh9nc | the beginning of another SARS- like pandemic? |
| cord-338538-uea9kwge | A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine Bioengineering bacterial outer membrane vesicles as vaccine platform Bacterial outer membrane vesicles: New insights and applications Meningococcal serogroup B vaccines: Will they live up to expectations? |
| cord-353161-mtq6yh25 | Can structural modeling predict cross- species transmission of SARS- CoV-2? |
| cord-353161-mtq6yh25 | Ready To Predict Interactomes? |
| cord-321918-9jwma2y6 | Human monoclonal antibodies block the binding of SARS- CoV-2 spike protein to angiotensin converting enzyme 2 receptor A human monoclonal antibody blocking SARS- CoV-2 infection Rapid selection of a human monoclonal antibody that potently neutralizes SARS- CoV-2 in two animal models Therapeutic potential of small molecules and engineered proteins What are the drugs of the future? |
| cord-321918-9jwma2y6 | Prim Care Meta- analysis: convalescent blood products for spanish influenza pneumonia: a future h5n1 treatment? |
| cord-321918-9jwma2y6 | Targeting membrane- bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus Angiotensin- converting enzyme 2: cardioprotective player in the renin- angiotensin system? |
| cord-333703-1ku3jc9s | The Heart in COVID-19: Primary Target or Secondary Bystander? |
| cord-333703-1ku3jc9s | different from other PVOD? |
| cord-332948-h297ukuu | Can We Rely on Computational Predictions To Correctly Identify Ligand Binding Sites on Novel Protein Drug Targets? |
| cord-332948-h297ukuu | r o o f resolution silico assessment of potential druggable pockets on the surface of?? |
| cord-332948-h297ukuu | r o o f resolution silico assessment of potential druggable pockets on the surface of?? |
| cord-340960-abanr641 | 182 pediatric COVID-19 patients with different severities and allergic status Blood Myeloperoxidase- DNA, a biomarker of early response to SARS- CoV-2 infection? |
| cord-340960-abanr641 | Allergy Clinical characteristics of 140 patients infected with SARS- CoV-2 in Wuhan Is global BCG vaccination- induced trained immunity relevant to the progression of SARS- CoV-2 pandemic? |
| cord-340960-abanr641 | do we know so far? |
| cord-338517-1mxcssjj | ( H1N1) 2009 virus infection Read in the Section on Diseases of Children, at the Forty- fourth Annual Meeting of the American Medical Association Meta- Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? |
| cord-338517-1mxcssjj | A possible role for B cells in COVID-19?: |
| cord-338517-1mxcssjj | Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients? |
| cord-338517-1mxcssjj | Is COVID-19 receiving ADE from other coronaviruses? |